Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.



home / news releases / CPRX - Catalyst Pharma in Sen. Sanders' crosshairs over Firdapse pricing; shares down 4% premarket


CPRX - Catalyst Pharma in Sen. Sanders' crosshairs over Firdapse pricing; shares down 4% premarket

  • Catalyst Pharmaceuticals (NASDAQ:CPRX) is down 4% premarket on light volume on the heels of the news that Sen. Bernie Sanders (I-VT) has sent it a letter asking why Firdapse (amifampridine), approved by the FDA about two months ago for the treatment of a rare autoimmune disorder called Lambert-Eaton myasthenic syndrome, costs $375K when patients were previously getting it for free.
  • More news on: Catalyst Pharmaceuticals, Inc.,
  • Read more ...
Stock Information

Company Name: Catalyst Pharmaceuticals Inc.
Stock Symbol: CPRX
Market: NASDAQ
Website: catalystpharma.com

Menu

CPRX CPRX Quote CPRX Short CPRX News CPRX Articles CPRX Message Board
Get CPRX Alerts

News, Short Squeeze, Breakout and More Instantly...